A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients

Completed · Phase 3

Conditions studied: HIV Infections

In brief

To determine the proportion of patients whose plasma HIV-1 RNA level falls below the level of detection (\< 400 copies/ml) at week 24 of study therapy. To determine the absolute change in plasma HIV-1 RNA during the 24 weeks of study treatment. To collect safety data on the treatment regimens. AS PER AMENDMENT 12/12/97: To compare the virologic response of Fortovase (FTV) (Saquinavir) Soft Gel Capsule (SGC) tid plus nucleoside reverse transcriptase inhibitors (NRTIs) versus FTV bid plus NRTIs. Further, to compare the virologic response of FTV tid plus NRTIs versus FTV bid plus Nelfinavir bid plus a NRTI with respect to: the percentage of patients whose plasma HIV-1 RNA level falls below the Amplicor assay level of detection (\< 400 copies/ml) at week 24 and week 48.

Key facts

Study ID

NCT00002378

Run by

Hoffmann-La Roche

People needed

825

Last updated by the study team

2005-06-24

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have:
• HIV-1 infection.
• HIV RNA >= 5000 copies/ml by Amplicor assay.
• Signed, informed consent from parent or legal guardian for patients less than 18 years old.
• Prior Medication:
• Required:
• (Note:
• 50% of the patients will be treatment naive).
• > 3 months cumulative therapy with antiretrovirals other than non-nucleoside reverse transcriptase inhibitors and/or protease inhibitors.
• Stable antiretroviral therapy for at least 4 weeks prior to enrollment.
• Allowed:
• <= 2 weeks cumulative treatment with protease inhibitors.
• AS PER AMENDMENT 12/12/97:
• Required:
• NRTI experienced patients:
• > 3 months cumulative therapy with antiretrovirals.
• <= 2 weeks cumulative previous treatment with non-nucleoside analogue reverse transcriptase inhibitors (NNRTIs).
• <= 2 weeks cumulative previous treatment with protease inhibitors.
• Must have at least one NRTI (preferably two) to which he/she has not been previously exposed.
• Stable antiretroviral therapy defined as within (+/-) 1 log HIV-1 RNA between the 2 most recent values greater than 8 weeks apart (may include screening visit) prior to study enrollment. (NOTE:
• If patient does not have a previous HIV-1 RNA value, screening will be accepted.)
• Required:
• Note:
• 50% of the patients will be treatment naive and 50% will be NRTI experienced. AS PER AMENDMENT 12/12/97.

Where it is running

• CIGNA — Phoenix, Arizona, United States
• Arizona Clinical Research Ctr Inc — Tucson, Arizona, United States
• Univ of Arizona — Tucson, Arizona, United States
• Alta Bates Med Ctr — Berkeley, California, United States
• Ctr for Special Immunology — Irvington District, California, United States
• AIDS Healthcare Foundation Labs — Los Angeles, California, United States
• Beer Med Group — Los Angeles, California, United States
• Dr Charles Farthing — Los Angeles, California, United States
• Gottlieb Med Group — North Hollywood, California, United States
• Dr Wilbert Jordan — Paramount, California, United States
• AIDS Community Research Consortium — Redwood City, California, United States
• Dr Daniel Pearce — San Francisco, California, United States
• UCSF - San Francisco Gen Hosp — San Francisco, California, United States
• Kaiser Permanente Med Ctr — San Francisco, California, United States
• QUEST Clinical Research — San Francisco, California, United States
• Marin County Specialty Clinic — San Rafael, California, United States
• Shared Med Research Foundation — Tarzana, California, United States
• Denver Public Health Dept / Disease Control Services — Denver, Colorado, United States
• Kaiser Permanente, Infectious Disease — Denver, Colorado, United States
• Georgetown Univ Med Ctr — Washington D.C., District of Columbia, United States
• Anderson Clinical Research — Washington D.C., District of Columbia, United States
• Providence Hosp — Washington D.C., District of Columbia, United States
• IDC Research Initiative — Altamonte Springs, Florida, United States
• Urgent Care Ctr — Fort Lauderdale, Florida, United States
• ASC Inc — Anniston, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.